Silencing HMGB1 expression inhibits adriamycin's heart toxicity via TLR4 dependent manner through MAPK signal transduction


Taskin E., Guven C., Kaya S. T., Sariman M., EMRENCE Z., Ekmekci S. S., ...More

JOURNAL OF BUON, vol.25, no.1, pp.554-565, 2020 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 25 Issue: 1
  • Publication Date: 2020
  • Journal Name: JOURNAL OF BUON
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, EMBASE, MEDLINE
  • Page Numbers: pp.554-565
  • Keywords: adriamycin, HMGB1, AMPK, TLR4, apoptosis, cardiac muscle cell, MITOCHONDRIAL DYSFUNCTION, INDUCED CARDIOTOXICITY, DOXORUBICIN, AMPK, CELLS, LIVER
  • Istanbul University Affiliated: Yes

Abstract

Purpose: Adriamycin (APR) is a commonly used anti-cancer drug. ADR has toxic effects on cardiomyocytes and leads to heart failure. However, the underlying mechanism(s) by which ADR causes heart failure is still not clarified exactly. The aim of present study is to investigate whether ADR-induced heart failure is mediated via HMGB1/TLR4 to initiate the apoptosis through MAPK/AMPK pathways.